LA STEATOSI NON ALCOLICA (NASH) AUMENTA IL RISCHIO DI EVENTI CARDIOVASCOLARI. UNA META-ANALISI DAL GRUPPO ITALIANO DI VERONA SU “LANCET”

Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis Alessandro Mantovan et al. Summary Background Studies have reported a significant association between non-alcoholic fatty liver disease (NAFLD) and increased incidence of cardiovascular disease (CVD). However, the magnitude of the risk and whether this risk changes with…

ANCORA SUL VALORE DELLA “P”. UNA INTERPRETAZIONE BAYESIANA DELLA SIGNIFICATIVITA’ !

Bayesian interpretation of p values in clinical trials   John Ferguson Abstract Commonly accepted statistical advice dictates that large-sample size and highly powered clinical trials generate more reliable evidence than trials with smaller sample sizes. This advice is generally sound: treatment effect estimates from larger trials tend to be more accurate, as witnessed by tighter…

I FARMACI ANTIDIABETICI PER LA STEATOSI NON ALCOLICA IN CORSO DI DIABETE: UNA META-ANALISI “NETWORK”

Anti-Diabetic Medications for Type 2 Diabetics with Non-Alcoholic Fatty Liver Disease. Evidence from a Network Meta-Analysis of Randomised Controlled Trials Cheng Han Ng, et al. Highlights • PPARγ agonists was ranked the best treatment for steatosis reduction. • SLGT2i was ranked the best treatment for fibrosis reduction • GLP-1RA and SGLT2i are superior for BMI reduction…

I MIGLIORI 10 PAPERS SULLA EBM (E PER INSEGNARLA!): IL WORKSHOP “SICILIA 2019” IN COLLABORAZIONE CON IL GRUPPO ITALIANO EBM

TEN PAPERS FOR TEACHERS OF EVIDENCE-BASED MEDICINE AND HEALTH CARE. THE SICILY WORKSHOP 2019 David Nunan et al. Introduction A previous article sought to signpost papers that were considered helpful when starting on the journey of practicing evidence-based medicine (EBM).1 The lead author was invited to run a workshop at the Eighth Conference of the…

GASTROPARESI: EPIDEMIOLOGIA E TERAPIE DI REAL-WORLD EVIDENCE. UNO STUDIO SU GASTROENTEROLOGY DAL GRUPPO DI CAMILLERI

Epidemiology, etiology and treatment of gastroparesis: real-world evidence from a large US national claims database Y. Ye et al. Background & Aims While gastroparesis carries a considerable healthcare and patient burden, associated epidemiological data are limited. To provide new real-world evidence for gastroparesis, we estimated disease prevalence, and investigated patient demographics and disease etiology in…

LE NUOVE TERAPIE BIOLOGICHE E CON “SMALL MOLECULES” PER LE IBD. UNA GRANDE REVISIONE DAL NEJM

Newer Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease Daniel C. Baumgart et al. Crohn’s disease and ulcerative colitis, together referred to as inflammatory bowel disease (IBD), are chronic systemic inflammatory disorders.1 These conditions target primarily the gastrointestinal tract but can affect many organ systems through extraintestinal manifestations (e.g., peripheral and axial arthritis, episcleritis, primary…